Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites

Area of Science:

• Parasitology
• Infectious Diseases
• Drug Discovery

Background:

• Current toxoplasmosis treatments fail to eradicate latent Toxoplasma gondii infections, leading to relapse in immunocompromised and congenitally infected patients.
• Existing drugs can cause bone marrow toxicity, highlighting the need for safer and more effective therapies.

Purpose of the Study:

• To identify novel drug lead compounds for treating toxoplasmosis with efficacy against latent infection.
• To develop a new method for evaluating anti-Toxoplasma drug candidates, specifically targeting bradyzoite forms.

Main Methods:

• Screened 878 compounds from a chemical library for anti-Toxoplasma activity and host cell cytotoxicity.
• Evaluated the effect of promising compounds on bradyzoite formation in vitro.
• Determined IC50 values for parasite growth inhibition and assessed host cell viability.

Main Results:

• 83 compounds inhibited >90% of parasite growth; 2, tanshinone IIA and hydroxyzine, were selected based on low host cell toxicity.
• Tanshinone IIA (IC50=2.5 μM) and hydroxyzine (IC50=1.0 μM) inhibited parasite replication and reduced bradyzoite numbers.
• Unlike current therapy pyrimethamine, both compounds demonstrated efficacy against bradyzoites, suggesting potential to eliminate latent infection.

Conclusions:

• Tanshinone IIA and hydroxyzine are potent lead compounds for developing new toxoplasmosis drugs.
• The novel evaluation method targeting bradyzoites offers a promising strategy for eradicating latent Toxoplasma gondii infections and preventing relapse.